Atara Biotherapeutics (ATRA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atara Biotherapeutics, Inc. has announced the termination of its Executive Vice President, Chief Medical Officer’s employment, effective February 2, 2024, due to a workforce reduction. The outgoing executive, Dr. Joshi, will continue to provide services under a consulting agreement until January 31, 2025, earning a monthly fee of $3,000 plus additional hourly compensation. Dr. Joshi’s equity awards will also vest during this period, and he may receive a significant bonus upon FDA approval of a key biologics license application.
For further insights into ATRA stock, check out TipRanks’ Stock Analysis page.